Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 17;5(7):e1331. doi: 10.1038/cddis.2014.286

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

PMC Copyright notice

Effect of TRAIL administration on neuroprotection elicited by ischemic preconditioning. (a) 6 μg/kg TRAIL i.c.v. administered determines the loss of the neuroprotection elicited by ischemic PC. Infarct volume in rats subjected to tMCAO+Vehicle, tMCAO+0.2 μg/kg TRAIL, tMCAO+6 μg/kg TRAIL, PC+tMCAO+Vehicle, PC+tMCAO+0.2 μg/kg TRAIL, and PC+tMCAO+6 μg/kg TRAIL. Rats were euthanized 24 h after tMCAO. *P<0.05 versus all experimental groups. Each column represents the mean±S.E.M. (n=3–7) of the percentage of the infarct volume compared with the ipsilateral hemisphere. (b) A total of 6 μg/kg TRAIL i.c.v. administered worsens general and focal deficits in rats subjected to PC+tMCAO. *P<0.05 versus PC+vehicle-treated animals